|View printer-friendly version|
ASLAN Pharmaceuticals Completes First Part of Single Ascending Dose Study for ASLAN004 Targeting Atopic Dermatitis
The phase 1 SAD study was conducted at a single site in
In the second part of the ongoing SAD study, a subcutaneous formulation is being tested. ASLAN dosed the last patient on 27 March and will report data from the second part of the study in May. ASLAN plans to initiate a multiple ascending dose study in moderate to severe atopic dermatitis patients in the second half of 2019.
Atopic dermatitis (AD) is the most common dermatological disease, affecting over 200 million patients worldwide1, characterised by red inflamed skin and severe daytime and night time itching, which can severely impact patients’ quality of life. In the US, it is estimated that AD occurs in 7.3% of adults2 whilst the global atopic dermatitis market is estimated to reach
Media and IR contacts
ASLAN004 is a fully human monoclonal antibody that targets the IL-13 receptor α1 subunit, or IL-13Rα1, with potential to be a best-in-class therapy. By targeting IL-13Rα1, ASLAN004 potently inhibits signalling of both interleukin 4, or IL-4, and interleukin 13, or IL-13. IL-4 and IL-13 are central to triggering symptoms of allergy in atopic dermatitis, such as redness and itching of the skin, as well as asthma symptoms such as shortness of breath, wheezing and coughing.
Forward looking statements
All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.
Source: ASLAN Pharmaceuticals Limited